{"id":"clarithromycin-placebo-tablets","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Clarithromycin placebo tablets contain no active drug substance and are used as a control comparator in clinical trials. They are designed to be indistinguishable from active clarithromycin tablets to maintain blinding in phase 3 studies, allowing researchers to isolate the true therapeutic effect of the active drug from placebo response.","oneSentence":"This is a placebo tablet with no active pharmacological mechanism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:06:17.108Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Control arm in phase 3 clinical trial (active indication unknown)"}]},"trialDetails":[{"nctId":"NCT07104318","phase":"PHASE3","title":"Personalized vs Standard of Care Treatment for Helicobacter Pylori Eradication Among Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-04-01","conditions":"Helicobacter Pylori","enrollment":360},{"nctId":"NCT06294600","phase":"PHASE3","title":"Clarithromycin Treatment to Prevent Sepsis Progression in CAP (REACT)","status":"RECRUITING","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2024-02-12","conditions":"Community-acquired Pneumonia","enrollment":330},{"nctId":"NCT06751121","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of DWP14012-based Triple Therapy in Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Daewoong Pharmaceutical Co. LTD.","startDate":"2024-02-06","conditions":"Helicobacter Pylori Infection, Helicobacter Pylori Infected Patients, Helicobacter Pylori Infected Subjects","enrollment":461},{"nctId":"NCT05857163","phase":"PHASE3","title":"Efficacy and Safety of Rifasutenizol (TNP 2198), Rabeprazole and Amoxicillin in Participants With H. Pylori Infection","status":"COMPLETED","sponsor":"TenNor Therapeutics (Suzhou) Limited","startDate":"2023-05-18","conditions":"H.Pylori Infection","enrollment":700},{"nctId":"NCT05577468","phase":"PHASE3","title":"Efficacy and Safety of Tegoprazan Versus Esomeprazole-containing Bismuth Quadruple Therapy for Eradication of Helicobacter Pylori","status":"COMPLETED","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2022-10-30","conditions":"Helicobacter Pylori Infection","enrollment":561},{"nctId":"NCT04724044","phase":"PHASE3","title":"Anti-inflammatory Action of Oral Clarithromycin in Community-acquired Pneumonia","status":"COMPLETED","sponsor":"Hellenic Institute for the Study of Sepsis","startDate":"2021-01-25","conditions":"Community-acquired Pneumonia, Sepsis, Inflammatory Response","enrollment":278},{"nctId":"NCT05716854","phase":"PHASE1","title":"Electrophysiological Effects of Potential QT Prolonging Drugs","status":"COMPLETED","sponsor":"Food and Drug Administration (FDA)","startDate":"2023-03-21","conditions":"Drug-induced QT Prolongation, Pharmacokinetics, Pharmacodynamics","enrollment":44},{"nctId":"NCT03824847","phase":"PHASE4","title":"Immunomodulatory Effect of Macrolides in Naturally Occurring Influenza Virus Infections in the Community","status":"SUSPENDED","sponsor":"The University of Hong Kong","startDate":"2023-06-01","conditions":"Influenza, Human","enrollment":100},{"nctId":"NCT05417997","phase":"PHASE3","title":"Effect of Kunamin in SARS-CoV-2 RT-PCR Positive Covid-19 Patients","status":"COMPLETED","sponsor":"RAAS Nutritionals, LLC","startDate":"2021-05-29","conditions":"COVID-19 Respiratory Infection, FLU, Cold; Influenza","enrollment":71},{"nctId":"NCT01506986","phase":"PHASE4","title":"Helicobacter Eradication Aspirin Trial","status":"COMPLETED","sponsor":"University of Nottingham","startDate":"2012-03","conditions":"Gastrointestinal Ulcer Haemorrhage, Bacterial Infection Due to Helicobacter Pylori (H. Pylori)","enrollment":30024},{"nctId":"NCT03050307","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-17","conditions":"Gastric Ulcer","enrollment":234},{"nctId":"NCT03050359","phase":"PHASE3","title":"Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Duodenal Ulcer Participants With or Without Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Takeda","startDate":"2017-04-05","conditions":"Duodenal Ulcer","enrollment":533},{"nctId":"NCT02829983","phase":"NA","title":"Clarithromycin as Adjuvant to Periodontal Debridement","status":"COMPLETED","sponsor":"Universidade Estadual Paulista Júlio de Mesquita Filho","startDate":"2014-03","conditions":"Aggressive Periodontitis","enrollment":40},{"nctId":"NCT02573935","phase":"PHASE2","title":"Clarithromycin in Multiple Myeloma Induction Therapy","status":"TERMINATED","sponsor":"Henrik Gregersen","startDate":"2015-01","conditions":"Multiple Myeloma","enrollment":58},{"nctId":"NCT01593592","phase":"NA","title":"Lactobacillus Reuteri in Management of Helicobacter Pylori Infection in Dyspeptic Patients","status":"COMPLETED","sponsor":"Zagazig University","startDate":"2012-06","conditions":"Helicobacter Pylori Infection","enrollment":70},{"nctId":"NCT01505127","phase":"PHASE3","title":"Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori","status":"COMPLETED","sponsor":"Takeda","startDate":"2012-01","conditions":"H. Pylori Infection","enrollment":650},{"nctId":"NCT00269386","phase":"PHASE3","title":"Clarithromycin in Active Crohn's Disease","status":"COMPLETED","sponsor":"Royal Liverpool University Hospital","startDate":"2000-04","conditions":"Crohn's Disease","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Clarithromycin placebo","Clarithromycin","ABT-268","Biaxin","clarithromycin"],"phase":"phase_3","status":"active","brandName":"Clarithromycin placebo tablets","genericName":"Clarithromycin placebo tablets","companyName":"TenNor Therapeutics (Suzhou) Limited","companyId":"tennor-therapeutics-suzhou-limited","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a placebo tablet with no active pharmacological mechanism. Used for Control arm in phase 3 clinical trial (active indication unknown).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}